LSU Health New Orleans is conducting a clinical trial, studying the use of liquid aspirin for early COVID. Associate Professor of Surgery Dr. Frank Lau said liquid aspirin isn’t widely available in the U.S. and because it acts as an anticoagulant it could help prevent blood clots that are common with COVID.
“The other way that this could help is that aspirin has anti-inflammatory properties. Kind of just clamping down a little bit of the over-exuberant immune response may also be able to help,” said Lau.
Lau said they are looking for 200 unvaccinated participants, who have recently been diagnosed with COVID to see if liquid aspirin can reduce severe COVID and hospitalization.
“And we would get them all set up with the aspirins and the blood draws that are needed, and also some follow-up to make sure they’re not getting sick from their COVID, and we would kind of get things going from there,” said Lau.
The study is expected to last four months for the first part and Lau said ideally participants would live in metro New Orleans.
“Because we have to deliver medications and do blood draws on them but it’s not too easy to find that many unvaccinated patients these days so we’re willing to range a little further field,” said Lau.
For information about the COVID liquid aspirin trial call 504-568-2202 or click here.
Comments